StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
34
This month
1
This year
3
Publishing Date
2024 - 04 - 08
1
2024 - 02 - 07
1
2024 - 01 - 23
1
2023 - 12 - 18
1
2023 - 12 - 13
1
2023 - 11 - 21
1
2023 - 10 - 21
1
2023 - 10 - 03
1
2023 - 06 - 19
1
2023 - 03 - 03
1
2023 - 01 - 26
1
2022 - 11 - 30
1
2022 - 11 - 14
1
2022 - 06 - 06
1
2022 - 05 - 11
1
2022 - 05 - 02
1
2022 - 04 - 01
1
2022 - 03 - 16
2
2022 - 03 - 01
2
2021 - 09 - 28
1
2021 - 09 - 27
2
2021 - 08 - 31
1
2021 - 08 - 05
1
2021 - 06 - 07
2
2021 - 05 - 21
2
2021 - 04 - 13
1
2021 - 04 - 11
1
2021 - 03 - 29
1
2021 - 03 - 17
1
Sector
Commercial services
1
Health technology
34
Tags
Aci-24
1
Aci-24.060
1
Active
1
Alliances
2
Alzheimer
1
Alzheimer's
2
Alzheimer's disease
1
Alzheimer’s
2
Anti-amyloid beta
1
Antibody
1
Asia
1
Aspen-06
1
Association
1
Authorization
2
Biomidwest
1
Biopharma
1
Biotech
3
Breast
1
Cancer
12
Cel
2
Cell
1
Ceo
1
China
1
Clinical-trials-phase-ii
2
Clinical-trials-phase-iii
3
Colorectal cancer
1
Congress
1
Covid
4
Covid-19
2
Designation
2
Disease
3
Ema
2
Emergency use authorization
2
Fda
4
Gastrointestinal
1
Growth
3
Heart
6
Iot
3
Kidney
2
Lung cancer
2
Market
3
N/a
22
Phase 2
3
Phase 2b
2
Phase 3
3
Pos
2
Positive
30
Presentation
2
Research
2
Results
8
Retevmo
2
Risk
2
Sabizabulin
3
Study
5
Technology
3
Therapeutics
2
Therapy
2
Topline
6
Treatment
5
Trial
15
Entities
Abbvie inc.
32
Adial pharmaceuticals, inc
10
Alnylam pharmaceuticals, inc.
19
Amgen inc.
17
Annovis bio, inc.
10
Aquestive therapeutics, inc.
18
Arrival
33
Astellas pharma inc
16
Astrazeneca plc
18
Beigene, ltd.
21
Beyondspring, inc.
11
Biogen inc.
13
Biontech se
18
Bridgebio pharma, inc.
16
Bristol-myers squibb company
33
Celldex therapeutics, inc.
10
Clearside biomedical, inc.
15
Coherus biosciences, inc.
24
Dare bioscience, inc.
13
Eli lilly and company
34
Fortress biotech, inc.
10
Gartner, inc.
31
Gilead sciences, inc.
14
Glaxosmithkline plc
13
Hoth therapeutics, inc.
14
I-mab
10
Immix biopharma, inc.
11
Immutep limited
12
In8bio inc
10
Incyte corporation
17
Ionis pharmaceuticals, inc.
21
Johnson & johnson
55
Kering
13
Lithium corp
18
Mediwound ltd.
11
Merck & company, inc.
21
Morgan stanley
12
Myovant sciences ltd.
10
Nasdaq, inc.
86
Novartis ag
25
Orange
40
Parsons corporation
14
Pds biotechnology corporation
12
Pfizer, inc.
46
Pliant therapeutics, inc.
10
Regeneron pharmaceuticals, inc.
26
Regenxbio inc.
17
Rocket pharmaceuticals, inc.
11
Sanofi
114
Scynexis, inc.
11
Seagen inc.
13
Sellas life sciences group, inc.
11
Sorrento therapeutics, inc.
22
Takeda pharmaceutical company limited
15
Taylor devices, inc.
17
Teva pharmaceutical industries ltd
14
Tonix pharmaceuticals holding corp.
12
Vertex pharmaceuticals incorporated
11
Viracta therapeutics inc
14
Zai lab limited
11
Symbols
ACIU
2
AKUS
1
ALNY
1
ALXO
1
BGNE
1
GLPG
1
GLPGF
1
GSK
3
IMAB
1
INCY
4
JNJ
1
KNSA
1
LLY
34
LNTH
1
MOR
1
MPSYF
1
NVO
1
PFE
1
PNT
1
RIGL
1
SNY
5
SNYNF
2
VERU
3
VIR
3
Exchanges
Nasdaq
20
Nyse
34
Crawled Date
2024 - 04 - 08
1
2024 - 02 - 07
1
2024 - 01 - 23
1
2023 - 12 - 18
1
2023 - 12 - 13
1
2023 - 11 - 21
1
2023 - 10 - 21
1
2023 - 10 - 03
1
2023 - 06 - 19
1
2023 - 03 - 03
1
2023 - 01 - 26
1
2022 - 12 - 01
1
2022 - 11 - 14
1
2022 - 06 - 06
1
2022 - 05 - 11
1
2022 - 05 - 02
1
2022 - 04 - 01
1
2022 - 03 - 16
2
2022 - 03 - 01
2
2021 - 09 - 28
1
2021 - 09 - 27
2
2021 - 08 - 31
1
2021 - 08 - 05
1
2021 - 06 - 07
2
2021 - 05 - 21
2
2021 - 04 - 13
1
2021 - 04 - 11
1
2021 - 03 - 29
1
2021 - 03 - 17
1
Crawled Time
00:00
3
01:00
1
02:00
1
07:00
1
10:00
1
11:00
4
12:00
2
12:15
1
12:20
1
12:30
1
13:00
1
13:20
1
14:00
3
15:00
1
16:20
1
17:00
2
18:00
1
20:00
1
20:20
1
21:00
2
22:00
3
23:00
1
Source
www.biospace.com
12
www.globenewswire.com
7
www.hutch-med.com
1
www.prnewswire.com
14
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
positive
entities :
Eli lilly and company
save search
Giant-Cell Arteritis Market to Showcase Positive Growth at a CAGR of 9.3% by 2034 | DelveInsight
Published:
2024-04-08
(Crawled : 22:00)
- prnewswire.com
JNJ
|
News
|
$149.56
0.3%
0.0%
9.1M
|
Health Technology
|
-1.41%
|
O:
-0.3%
H:
0.0%
C:
0.0%
LLY
|
News
|
$745.69
1.96%
-0.16%
2M
|
Health Technology
|
-4.92%
|
O:
0.05%
H:
0.02%
C:
-2.62%
MOR
|
News
|
$18.04
0.45%
0.44%
180K
|
Health Technology
|
-0.61%
|
O:
0.06%
H:
0.22%
C:
0.0%
KNSA
|
$17.66
3.31%
3.2%
610K
|
Health Technology
|
0.0%
|
O:
0.23%
H:
1.58%
C:
0.06%
IMAB
|
$1.81
0.56%
0.55%
200K
|
Health Technology
|
-0.55%
|
O:
-0.55%
H:
1.39%
C:
0.0%
GLPG
|
News
|
$29.47
1.38%
1.36%
120K
|
Health Technology
|
-8.41%
|
O:
0.0%
H:
0.39%
C:
-0.66%
positive
growth
market
REVALESIO ANNOUNCES POSITIVE TOPLINE DATA FROM PHASE 2 RESCUE STUDY OF RNS60 IN PATIENTS WITH ACUTE ISCHEMIC STROKE IN LATE-BREAKING ORAL PRESENTATION AT ISC 2024
Published:
2024-02-07
(Crawled : 23:00)
- biospace.com/
LLY
|
News
|
$745.69
1.96%
-0.16%
2M
|
Health Technology
|
4.83%
|
O:
0.76%
H:
4.31%
C:
2.11%
rns60
stroke
presentation
positive
topline
study
Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting
Published:
2024-01-23
(Crawled : 17:00)
- prnewswire.com
LLY
|
News
|
$745.69
1.96%
-0.16%
2M
|
Health Technology
|
17.15%
|
O:
-0.51%
H:
0.37%
C:
0.32%
genetic
association
positive
research
meeting
trial
therapy
Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer
Published:
2023-12-18
(Crawled : 12:30)
- globenewswire.com
PNT
|
$13.68
2.63%
0.15%
0
|
|
-9.84%
|
O:
-10.09%
H:
0.0%
C:
0.0%
LLY
|
News
|
$745.69
1.96%
-0.16%
2M
|
Health Technology
|
30.27%
|
O:
1.61%
H:
1.14%
C:
0.57%
LNTH
|
$64.41
2.13%
2.08%
590K
|
Health Technology
|
-15.29%
|
O:
-19.87%
H:
5.04%
C:
-8.75%
positive
cancer
biopharma
topline
trial
results
Metastatic Prostate Cancer Market to Exhibit Positive Growth at a CAGR of 22% and 7.5% for mHSPC and mCRPC, respectively During the Study Period (2019-2032), Assesses DelveInsight
Published:
2023-12-13
(Crawled : 22:00)
- prnewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-1.74%
|
O:
0.25%
H:
0.0%
C:
0.0%
LLY
|
News
|
$745.69
1.96%
-0.16%
2M
|
Health Technology
|
26.72%
|
O:
1.8%
H:
0.0%
C:
0.0%
SNY
|
News
|
$47.69
1.15%
1.13%
1.7M
|
Health Technology
|
-2.57%
|
O:
0.0%
H:
0.0%
C:
0.0%
positive
cancer
growth
study
market
Kiyatec strengthens its leadership position with the addition of Mark Capone, former CEO of Myriad Genetics, as Strategic Advisor
Published:
2023-11-21
(Crawled : 18:00)
- biospace.com/
LLY
|
News
|
$745.69
1.96%
-0.16%
2M
|
Health Technology
|
23.67%
|
O:
0.07%
H:
0.0%
C:
0.0%
ceo
Lilly's Retevmo® (selpercatinib) Phase 3 Results in RET Fusion-Positive Non-Small Cell Lung Cancer and RET-Mutant Medullary Thyroid Cancer Both Published in The New England Journal of Medicine and Presented in a Presidential Symposium at ESMO Congress 2023
Published:
2023-10-21
(Crawled : 16:20)
- prnewswire.com
LLY
|
News
|
$745.69
1.96%
-0.16%
2M
|
Health Technology
|
Email alert
Add to watchlist
retevmo
lung
congress
symposium
cancer
cell
thyroid
results
ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
Published:
2023-10-03
(Crawled : 10:00)
- globenewswire.com
LLY
|
News
|
$745.69
1.96%
-0.16%
2M
|
Health Technology
|
37.87%
|
O:
0.19%
H:
0.0%
C:
0.0%
ALXO
M
|
$15.5
8.92%
8.19%
440K
|
Commercial Services
|
222.25%
|
O:
68.19%
H:
2.84%
C:
-7.17%
aspen-06
positive
cancer
treatment
trial
results
Alopecia Areata Market to Show Positive Growth at a CAGR of 26.3% During the Study Period (2019-2032), Estimates DelveInsight
Published:
2023-06-19
(Crawled : 20:00)
- prnewswire.com
LLY
|
News
|
$745.69
1.96%
-0.16%
2M
|
Health Technology
|
65.07%
|
O:
-0.41%
H:
2.02%
C:
1.37%
SNY
|
News
|
$47.69
1.15%
1.13%
1.7M
|
Health Technology
|
-10.45%
|
O:
1.71%
H:
0.0%
C:
0.0%
INCY
|
$51.62
-0.58%
-0.58%
2.5M
|
Health Technology
|
-18.31%
|
O:
0.3%
H:
0.17%
C:
-2.63%
positive
show
growth
study
market
U.S. FDA Broadens Indication for Verzenio® (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer
Published:
2023-03-03
(Crawled : 21:00)
- prnewswire.com
LLY
|
News
|
$745.69
1.96%
-0.16%
2M
|
Health Technology
|
Email alert
Add to watchlist
verzenio
fda
risk
breast
cancer
AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial
Published:
2023-01-26
(Crawled : 12:20)
- globenewswire.com
LLY
|
News
|
$745.69
1.96%
-0.16%
2M
|
Health Technology
|
111.32%
|
O:
0.36%
H:
0.34%
C:
-0.85%
ACIU
|
$2.38
-1.65%
-1.68%
190K
|
Health Technology
|
1.71%
|
O:
10.68%
H:
0.0%
C:
-7.34%
aci-24
vaccine
trial
alzheimer’s
positive
aci-24.060
anti-amyloid beta
phase 2b
Lilly Shares Positive Donanemab Data in First Active Comparator Study in Early Symptomatic Alzheimer's Disease
Published:
2022-11-30
(Crawled : 00:00)
- prnewswire.com
LLY
|
News
|
$745.69
1.96%
-0.16%
2M
|
Health Technology
|
99.16%
|
O:
1.0%
H:
0.11%
C:
-1.19%
disease
active
alzheimer's
positive
study
HUTCHMED Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in Second-Line Gastric Cancer in China
Published:
2022-11-14
(Crawled : 00:00)
- hutch-med.com
LLY
|
News
|
$745.69
1.96%
-0.16%
2M
|
Health Technology
|
109.78%
|
O:
1.92%
H:
0.48%
C:
-0.84%
BGNE
|
$139.22
6.32%
5.95%
200K
|
Health Technology
|
-29.79%
|
O:
3.05%
H:
1.74%
C:
-0.5%
topline
china
positive
cancer
study
Veru Announces Presentation of Final Positive Phase 1b/2 Clinical Trial Results for Sabizabulin in Metastatic Castration Resistant Prostate Cancer at the 2022 American Society of Clinical Oncology Annual Meeting
Published:
2022-06-06
(Crawled : 11:00)
- globenewswire.com
LLY
|
News
|
$745.69
1.96%
-0.16%
2M
|
Health Technology
|
143.88%
|
O:
3.83%
H:
0.0%
C:
0.0%
VERU
|
$1.27
0.0%
2.6M
|
Health Technology
|
-90.26%
|
O:
10.2%
H:
0.0%
C:
0.0%
sabizabulin
trial
presentation
positive
cancer
phase 2b
prostate cancer
FDA States that Veru Should Submit Request for Emergency Use Authorization (EUA) Based on Positive Efficacy and Safety Data from the Phase 3 Clinical Study of Sabizabulin in Hospitalized COVID-19 Patients
Published:
2022-05-11
(Crawled : 11:00)
- biospace.com/
LLY
|
News
|
$745.69
1.96%
-0.16%
2M
|
Health Technology
|
153.16%
|
O:
-3.03%
H:
0.0%
C:
0.0%
VERU
|
$1.27
0.0%
2.6M
|
Health Technology
|
-84.13%
|
O:
20.75%
H:
0.0%
C:
0.0%
covid-19
fda
sabizabulin
authorization
positive
phase 3
emergency use authorization
FDA Has Granted Veru a Pre-Emergency Use Authorization (EUA) Meeting Date for Positive Sabizabulin Phase 3 COVID-19 Study
Published:
2022-05-02
(Crawled : 13:20)
- biospace.com/
LLY
|
News
|
$745.69
1.96%
-0.16%
2M
|
Health Technology
|
151.11%
|
O:
-0.92%
H:
0.0%
C:
0.0%
VERU
|
$1.27
0.0%
2.6M
|
Health Technology
|
-89.16%
|
O:
8.28%
H:
2.44%
C:
-19.07%
covid-19
fda
sabizabulin
granted
authorization
positive
phase 3
emergency use authorization
Lilly Presents Updated Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Non-Small-Cell Lung Cancer (NSCLC) at the 2022 European Lung Cancer Congress
Published:
2022-04-01
(Crawled : 11:00)
- prnewswire.com
LLY
|
News
|
$745.69
1.96%
-0.16%
2M
|
Health Technology
|
158.08%
|
O:
-0.08%
H:
2.44%
C:
2.28%
retevmo
cancer
Lilly, BI-Partnered Kidney Trial Stopped Early Due to Positive Results
Published:
2022-03-16
(Crawled : 17:00)
- biospace.com/
LLY
|
News
|
$745.69
1.96%
-0.16%
2M
|
Health Technology
|
168.3%
|
O:
0.87%
H:
0.27%
C:
-0.51%
pos
kidney
trial
positive results
positive
results
Jardiance® phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease
Published:
2022-03-16
(Crawled : 14:00)
- biospace.com/
LLY
|
News
|
$745.69
1.96%
-0.16%
2M
|
Health Technology
|
168.3%
|
O:
0.87%
H:
0.27%
C:
-0.51%
jardiance
pos
kidney
trial
disease
positive
AnHeart Therapeutics and Innovent Biologics Receive NMPA Breakthrough Designation for Taletrectinib in ROS1 Fusion-Positive Non-Small Cell Lung Cancer
Published:
2022-03-01
(Crawled : 15:00)
- biospace.com/
LLY
|
News
|
$745.69
1.96%
-0.16%
2M
|
Health Technology
|
202.13%
|
O:
1.26%
H:
0.0%
C:
0.0%
INCY
|
$51.62
-0.58%
-0.58%
2.5M
|
Health Technology
|
-23.83%
|
O:
0.44%
H:
2.1%
C:
0.88%
heart
therapeutics
cel
lung cancer
positive
cancer
designation
← Previous
1
2
Next →
Gainers vs Losers
78%
22%
Top 10 Gainers
MTTR
|
News
4
|
$4.6
164.37%
62.17%
28M
|
AGBA
|
$2.94
135.2%
57.48%
66M
|
Finance
EDBL
|
News
|
$6.46
71.81%
41.8%
2M
|
MTC
|
$2.25
44.23%
30.67%
6M
|
Technology Services
OPRT
|
News
|
$3.175
41.11%
29.13%
12M
|
Finance
SHIM
|
$3.05
35.56%
26.23%
1.1M
|
HKIT
|
$1.345
31.86%
24.16%
390K
|
Technology Services
ABVC
|
$1.36
30.77%
23.53%
7.4M
|
Wholesale Trade
OST
|
$0.512
28.0%
21.88%
290K
|
POET
|
$1.59
27.2%
21.38%
4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.